Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Mus musculus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy control group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome group (PCOS)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 6
- Group 1 sample size Number of subjects in the case (exposed) group
- 6
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 3
Signature 1
Source: Figure 3B
Description: LDA (linear discriminant analysis) scores for the species abundance in the control and PCOS groups.
Abundance in Group 1: increased abundance in Polycystic ovary syndrome group (PCOS)
Signature 2
Source: Figure 3B
Description: LDA (linear discriminant analysis) scores for the species abundance in the control and PCOS groups.
Abundance in Group 1: decreased abundance in Polycystic ovary syndrome group (PCOS)
Experiment 2
Curated date: 2025/01/02
Curator:
Revision editor(s):
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Polycystic ovary syndrome (PCOS) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome + Liraglutide group (PCOS + Liraglutide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS) and then treated with liraglitude GLP-1RAs for 4 weeks.
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- decreased
Signature 1
Source: Figure 3C
Description: LDA scores for the species abundance in the PCOS and PCOS+Liraglutide groups.
Abundance in Group 1: increased abundance in
Signature 2
Source: Figure 3C
Description: LDA scores for the species abundance in the PCOS and PCOS+Liraglutide groups.
Abundance in Group 1: decreased abundance in
Experiment 3
Curated date: 2025/01/02
Curator:
Revision editor(s):
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome + Semaglutide group (PCOS + Semaglutide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS) and then treated with Semaglutide GLP-1RAs for 4 weeks.
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- decreased
Signature 1
Source: Figure 3D
Description: LDA scores for the species abundance in the PCOS and PCOS+Semaglutide groups.
Abundance in Group 1: increased abundance in
Signature 2
Source: Figure 3D
Description: LDA scores for the species abundance in the PCOS and PCOS+Semaglutide groups.
Abundance in Group 1: decreased abundance in
Experiment 4
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy control group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome group (PCOS)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS).
Lab analysis
Statistical Analysis
- Statistical test
- Kruskall-Wallis
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- Not specified
Signature 1
Source: Figure 2b, c, d & Figure 3e
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: increased abundance in Polycystic ovary syndrome group (PCOS)
| NCBI | Quality Control | Links |
|---|---|---|
| Muribaculaceae bacterium Isolate-037 (Harlan) | ||
| Bacteroidota | ||
| Muribaculaceae | ||
| Bacteroidaceae | ||
| Bacteroides | ||
| Lepagella muris | ||
| Lepagella | ||
| Bacteroides acidifaciens |
Signature 2
Source: Figure 2b
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: decreased abundance in Polycystic ovary syndrome group (PCOS)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillota | ||
| Bacillota/BacteroidotaBacillota/Bacteroidota |
Experiment 5
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Polycystic ovary syndrome (PCOS) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome + Liraglutide group (PCOS + Liraglutide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS) and then treated with liraglutide GLP-1RAs for 4 weeks.
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- decreased
Signature 1
Source: Figure 2b, c & d
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: increased abundance in Polycystic ovary syndrome + Liraglutide group (PCOS + Liraglutide)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillota | ||
| Bifidobacterium | ||
| Ileibacterium | ||
| Lachnospiraceae | ||
| Oscillospiraceae | ||
| Bacillota/BacteroidotaBacillota/Bacteroidota |
Signature 2
Source: Figure 2b, c, d & Figure 3e
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: decreased abundance in Polycystic ovary syndrome + Liraglutide group (PCOS + Liraglutide)
| NCBI | Quality Control | Links |
|---|---|---|
| Muribaculaceae bacterium Isolate-037 (Harlan) | ||
| Bacteroidota | ||
| Muribaculaceae | ||
| Bacteroidaceae | ||
| Lepagella | ||
| Bacteroides | ||
| Lepagella muris | ||
| Bacteroides acidifaciens |
Experiment 6
Curated date: 2025/01/14
Curator:
Revision editor(s):
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome + Semaglutide group (PCOS + Semaglutide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mice with Dehydroepiandrosterone (DHEA)-induced Polycystic ovary syndrome (PCOS) and then treated with Semaglutide GLP-1RAs for 4 weeks.
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- decreased
Signature 1
Source: Figure 2b, c, d & Figure 3e
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: increased abundance in
| NCBI | Quality Control | Links |
|---|---|---|
| Campylobacterota | ||
| Helicobacteraceae | ||
| Helicobacter | ||
| Alistipes muris |
Signature 2
Source: Figure 2d & Figure 3e
Description: Microbiota composition at the phylum, family, and genus level and the relative abundance of signatures among four groups.
Abundance in Group 1: decreased abundance in
| NCBI | Quality Control | Links |
|---|---|---|
| Lepagella | ||
| Bacteroides | ||
| Lepagella muris | ||
| Bacteroides acidifaciens | ||
| Muribaculaceae bacterium Isolate-037 (Harlan) |
